WO2009057138A3 - Compositions pharmaceutiques à libération régulée de toltérodine - Google Patents

Compositions pharmaceutiques à libération régulée de toltérodine Download PDF

Info

Publication number
WO2009057138A3
WO2009057138A3 PCT/IN2008/000695 IN2008000695W WO2009057138A3 WO 2009057138 A3 WO2009057138 A3 WO 2009057138A3 IN 2008000695 W IN2008000695 W IN 2008000695W WO 2009057138 A3 WO2009057138 A3 WO 2009057138A3
Authority
WO
WIPO (PCT)
Prior art keywords
tolterodine
controlled release
release pharmaceutical
pharmaceutical compositions
pharmaceutically acceptable
Prior art date
Application number
PCT/IN2008/000695
Other languages
English (en)
Other versions
WO2009057138A2 (fr
Inventor
Anirudha Bhagirath Kute
Rahul Manorajan Sammohi
Nikhil Prabhakar Malewar
Makarand Krishnakumar Avachat
Original Assignee
Lupin Ltd
Anirudha Bhagirath Kute
Rahul Manorajan Sammohi
Nikhil Prabhakar Malewar
Makarand Krishnakumar Avachat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd, Anirudha Bhagirath Kute, Rahul Manorajan Sammohi, Nikhil Prabhakar Malewar, Makarand Krishnakumar Avachat filed Critical Lupin Ltd
Priority to JP2010531645A priority Critical patent/JP2011502140A/ja
Publication of WO2009057138A2 publication Critical patent/WO2009057138A2/fr
Publication of WO2009057138A3 publication Critical patent/WO2009057138A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une composition pharmaceutique à libération régulée qui contient un noyau comportant de la toltérodine ou des sels acceptables du point de vue pharmaceutique de celle-ci, des excipients auxiliaires et une seule couche d'enrobage comportant un ou des agents de régulation de vitesse. L'invention porte également sur une composition pharmaceutique à libération régulée qui comporte de la toltérodine ou des sels acceptables du point de vue pharmaceutique de celle-ci, le noyau comportant de la toltérodine ou des sels acceptables du point de vue pharmaceutique de celle-ci, des excipients auxiliaires et une seule couche d'enrobage comportant un ou des agents de régulation de la vitesse, ladite composition comportant en outre un ou des agents améliorant la dissolution.
PCT/IN2008/000695 2007-10-29 2008-10-22 Compositions pharmaceutiques à libération régulée de toltérodine WO2009057138A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010531645A JP2011502140A (ja) 2007-10-29 2008-10-22 トルテロジンの制御放出型医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1475/KOL/2007 2007-10-29
IN1475KO2007 2007-10-29

Publications (2)

Publication Number Publication Date
WO2009057138A2 WO2009057138A2 (fr) 2009-05-07
WO2009057138A3 true WO2009057138A3 (fr) 2009-07-23

Family

ID=40405020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000695 WO2009057138A2 (fr) 2007-10-29 2008-10-22 Compositions pharmaceutiques à libération régulée de toltérodine

Country Status (2)

Country Link
JP (1) JP2011502140A (fr)
WO (1) WO2009057138A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CA2761602C (fr) * 2009-05-11 2015-07-07 Ratiopharm Gmbh Desfesoterodine sous forme de sel d'acide tartrique
TR201111143T1 (tr) * 2009-05-11 2012-05-21 Lupin Limited Yeni̇ farmasöti̇k koli̇n fenofi̇brat bi̇leşi̇mleri̇
ES2600894T3 (es) * 2010-02-22 2017-02-13 Daiichi Sankyo Company, Limited Preparación sólida de liberación sostenida para uso oral
WO2011102504A1 (fr) 2010-02-22 2011-08-25 第一三共株式会社 Préparation solide à libération prolongée pour utilisation orale
SG174658A1 (en) * 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
SG194809A1 (en) 2011-05-10 2013-12-30 Theravida Inc Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
WO2014034929A1 (fr) 2012-09-03 2014-03-06 第一三共株式会社 Composition pharmaceutique à libération prolongée administrée par voie orale contenant du chlorhydrate d'hydromorphone
CA2993823C (fr) 2015-07-28 2024-01-02 Board Of Regents, The University Of Texas System Compositions d'implant destinees a l'apport unidirectionnel de composes therapeutiques au cerveau
JP6841834B2 (ja) 2016-01-20 2021-03-10 テラヴィダ, インコーポレイテッドTheraVida, Inc. 多汗症の処置のための方法および組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105735A1 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Compositions pharmaceutiques de tolterodine a liberation controlee et leurs procedes de preparation
WO2005105036A1 (fr) * 2004-04-28 2005-11-10 Natco Pharma Limited Matrice muco-adhesive a liberation controlee contenant de la tolterodine, et procede d'elaboration
WO2007029087A2 (fr) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Preparations multi-unites a liberation controlee
WO2007113207A2 (fr) * 2006-03-31 2007-10-11 Lek Pharmaceuticals D.D. Formulations enduites
WO2008012346A1 (fr) * 2006-07-28 2008-01-31 Farmaprojects, S. A. Préparation pharmaceutique de métoprolol à libération prolongée et son procédé de préparation
WO2009019599A2 (fr) * 2007-08-08 2009-02-12 Themis Laboratories Private Limited Compositions à libération prolongée comprenant de la toltérodine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175414A (ja) * 1983-03-23 1984-10-04 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
JP2001316292A (ja) * 1999-09-03 2001-11-13 Takeda Chem Ind Ltd 医 薬

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105735A1 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Compositions pharmaceutiques de tolterodine a liberation controlee et leurs procedes de preparation
WO2005105036A1 (fr) * 2004-04-28 2005-11-10 Natco Pharma Limited Matrice muco-adhesive a liberation controlee contenant de la tolterodine, et procede d'elaboration
WO2007029087A2 (fr) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Preparations multi-unites a liberation controlee
WO2007113207A2 (fr) * 2006-03-31 2007-10-11 Lek Pharmaceuticals D.D. Formulations enduites
WO2008012346A1 (fr) * 2006-07-28 2008-01-31 Farmaprojects, S. A. Préparation pharmaceutique de métoprolol à libération prolongée et son procédé de préparation
WO2009019599A2 (fr) * 2007-08-08 2009-02-12 Themis Laboratories Private Limited Compositions à libération prolongée comprenant de la toltérodine

Also Published As

Publication number Publication date
WO2009057138A2 (fr) 2009-05-07
JP2011502140A (ja) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2009057138A3 (fr) Compositions pharmaceutiques à libération régulée de toltérodine
WO2007133583A3 (fr) Formes posologiques solides à libération modifiée d'ordre zéro
WO2006052575A3 (fr) Dispositif medical d'administration d'agents therapeutiques sur differentes periodes
WO2006084164A8 (fr) Systeme d'administration a retention gastrique et a liberation lente
WO2007103200A3 (fr) Formulation orale à libération contrôlée pour des agents sédatifs ou hypnotiques
WO2008033351A3 (fr) Formulations multimode de libération prolongée et résistantes à l'abus
WO2008011335A3 (fr) Composés fixant le métal, compositions fixant le métal, ainsi que leurs applications
WO2008010921A3 (fr) Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
WO2006007323A3 (fr) Formes posologiques pour agents pharmaceutiques exempts d'acides a taux de dissolution et/ou de solubilite bas
WO2009059701A3 (fr) Comprimés à libération prolongée contenant de l'hydromorphone
WO2007041367A3 (fr) Préparation orale contenant un agent induisant la salivation
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
WO2009034431A3 (fr) Formes posologiques à libération contrôlée de la varenicline
IL199077A (en) Oral Pharmaceutical Preparation Containing Fumarate Salt of (Alpha S, Beta R) -6- Bromo-Alpha- [2- (Dimethylamino) Ethyl] -2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolinethanol , Uses and process for making active material
WO2009047802A3 (fr) Nouvelle formulation bioadhésive à libération modifiée d'acide 5-aminosalicylique ou de ses sels et de ses métabolites destinée au traitement du colon
IL204500A (en) Process for manufacturing vehicle or pharmacist composition by spraying a coating of sodium picosulphate on a nucleus of potassium bicarbonate
WO2005123134A3 (fr) Systeme d'administration a liberation controlee pour metformine
WO2007146006A3 (fr) Composition d'oxycodone à libération prolongée comprenant un polymère acrylique et un tensioactif
WO2007021968A3 (fr) Composition antihistaminique et decongestionnante a liberation lente
WO2006072070A3 (fr) Formulations pharmaceutiques contenant des sels de gallium
PT1795186E (pt) Preparado farmacêutico compreendendo flupirtina com libertação controlada da substância activa
WO2009072334A1 (fr) Particule de cœur pour préparation pharmaceutique
EP1755568A4 (fr) Formulation a liberation lente pour l'administration orale de metformine
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
WO2009052353A3 (fr) Formulations pharmaceutiques de trospium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08844947

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010531645

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08844947

Country of ref document: EP

Kind code of ref document: A2